NCT02631876: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
- State
- Completed
- Phase
- Phase 3
- People
- 366 taking part
- Started
- 2 Mar 2016
- Primary completion
- Jan 2019
- Arms
- Investigator's Choice (IC) Chemotherapy
- Results
- Posted on the registry
- 16 Dec 2015: Trial registered
- 2 Mar 2016: Trial started
- 9 Jun 2020: Trial results posted